Abstracts Archive - Page 1568 of 2425 - ACR Meeting Abstracts

Abstract Number: 2262 • 2016 ACR/ARHP Annual Meeting
CR6086 a New Potent EP4 Receptor Antagonist with Immunomodulatory Activities
Tiziana Piepoli¹, Daniele Maggioni², Silvia Zerbi¹, Anna Stucchi¹, Laura Mennuni¹, Marco Lanza¹, Gianfranco Caselli¹ and Lucio Claudio Rovati¹, ¹Rottapharm Biotech, Monza, Italy, ²School of Medicine and Surgery, University of Milano-Bicocca, Monza, Italy
Background/Purpose: In the early phase of rheumatoid arthritis (RA), PGE2 recruits different immune cells from the blood stream into target tissues. Via the EP4 receptor,…
Abstract Number: 2263 • 2016 ACR/ARHP Annual Meeting
Apolipoprotein E Regulates Inflammation and Joint Destruction during Antigen-Induced Arthritis (AIA)
Giuliana Ascone¹, Irene Di Ceglie¹, Wouter de Munter¹, Birgitte Walgreen², Annet Sloetjes¹, Peter M. van der Kraan¹, Ernst Lindhout³, Mike Martens³ and Peter L. E. M. van Lent¹, ¹Experimental Rheumatology, Radboud university medical center, Nijmegen, Netherlands, ²Experimental, Radboud university medical center, Nijmegen, Netherlands, ³Future Diagnostics Solutions (FDs), Wijchen, Netherlands
Background/Purpose: Rheumatoid arthritis (RA) is a chronic inflammatory disease largely driven by immune complexes and their interaction with FcγRs present on macrophages within the synovium.…
Abstract Number: 2264 • 2016 ACR/ARHP Annual Meeting
Lack of Obesity-Related Changes in Adipocytes and Inflammatory Cells in the Infrapatellar Fat Pad (IFP): A Different Type of Fat?
Anja de Jong¹, I.R. klein-Wieringa¹, Stefan Andersen², Joanneke Kwekkeboom¹, Linda van Toorn¹, Badelog de Lange¹, Danny van Delft³, John Garcia⁴, Wu Wei⁵, Huub van der Heide³, Yvonne Bastiaansen-Jenniskens⁴, Gerjo van Osch⁴, Anne-Marie Zuurmond⁶, Vedrana Stojanovic-Susulic⁷, Rob Nelissen³, René Toes¹, Margreet Kloppenburg¹ and Andreea Ioan-Facsinay¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Charles River Nederland B.V., Leiden, Netherlands, ³Orthopaedics, Leiden University Medical Center, Leiden, Netherlands, ⁴Orthopaedics, Erasmus MC, Rotterdam, Netherlands, ⁵Orthopaedics, Erasmus MC, rotterdam, Netherlands, ⁶TNO, Leiden, Netherlands, ⁷Janssen, Pharmaceutical Companies Johnson & Johnson, Springhouse, PA
Background/Purpose: Obesity is associated with the development and progression of osteoarthritis (OA). Although the mechanisms involved in this association are poorly understood, it is well…
Abstract Number: 2265 • 2016 ACR/ARHP Annual Meeting
NET-Inducing Capacity Is a Biomarker in ANCA-Associated Vasculitis Independent of ANCA Antibodies
Tineke Kraaij¹, Sylvia Kamerling¹, Jaap Bakker², Francesca Brunini³, Charles Pusey³, Hans Ulrich Scherer⁴, René E.M. Toes⁵, Ton Rabelink¹, Cees van Kooten¹ and Onno Teng¹, ¹Nephrology, Leiden University Medical Center, Leiden, Netherlands, ²Clinical Chemistry, Leiden University Medical Center, Leiden, Netherlands, ³Imperial College, London, United Kingdom, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵Rheumatology, Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Neutrophil extracellular traps (NETs) play an important role in the pathogenesis of ANCA-associated vasculitis (AAV). Sera of MPO-ANCA or PR3-ANCA positive patients can induce…
Abstract Number: 2266 • 2016 ACR/ARHP Annual Meeting
A Melanocortin Fusion Peptide (AQB-565) Optimized for Melanocortin Receptor Engagement Significantly Reduces Inflammation in an In Vivo model of Acute Gout
Ronald Berenson¹, Maura-Ann Matthews¹, Wayne Wallis², Raj Dua¹, Margaret Moore¹, Robert Terkeltaub³ and Christopher Clegg^1,4, ¹Aequus BioPharma, Inc., Seattle, WA, ²Dyad Life Sciences, LLC, Seattle, WA, ³Medicine-Rheumatology, University of California, San Diego, La Jolla, CA, ⁴TRIA Bioscience, Seattle, WA
Background/Purpose: The melanocortins (MCs) are endogenous peptides (including ACTH, α-MSH and γ-MSH), which bind 5 G protein-coupled receptors (MCRs 1 through 5) with varying affinity.…
Abstract Number: 2267 • 2016 ACR/ARHP Annual Meeting
AMP-Activated Protein Kinase: A Target for Methotrexate in Macrophages
Cornelia Cudrici¹, Martin Pelletier² and Richard M. Siegel³, ¹NIAMS, Immunoregulation Section, Autoimmunity Branch, Bethesda, MD, ²Infectious and immune diseases Centre Hospitalier de l'Université Laval (CHUL) Québec, Québec, QC, Canada, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD
Background/Purpose: Methotrexate (MTX) remains a cornerstone of treatment in multiple forms of inflammatory arthritis, lupus and vasculitis. The anti-inflammatory effects of MTX are more likely…
Abstract Number: 2268 • 2016 ACR/ARHP Annual Meeting
Fructose Amplifies Inflammatory Potential in Human Monocytic Cells Via Reduction of AMP-Activated Protein Kinase Activity
Xihua Cao¹, Jeffrey N. Miner², Robert Terkeltaub^3,4 and Ru Liu-Bryan^1,4, ¹VA Medical Center, San Diego, CA, ²Discovery Biology, Ardea Biosciences, Inc., San Diego, CA, ³Rheumatology, VA Medical Center, San Diego, CA, ⁴Medicine-Rheumatology, University of California, San Diego, La Jolla, CA
Background/Purpose: High dietary content of fructose (in table sugar, sweetened sodas, energy beverages, and fruit juices) is a substantial risk factor for both hyperuricemia and…
Abstract Number: 2269 • 2016 ACR/ARHP Annual Meeting
Proteinaceous Amorphous Calcium Carbonates As a Novel Family of Crystals in Synovial Fluid from Symptomatic Joints
Bolan Li¹, Nora Singer^2,3 and Ozan Akkus^3,4, ¹Mechanical and Aerospace Engineering, Case Western Reserve University, Cleveland, OH, ²Medicine and Pediatrics, MetroHealth System, Cleveland, OH, ³Case Western Reserve University School of Medicine, Cleveland, OH, ⁴University Hospitals Case Medical Center, Cleveland, OH
Background/Purpose: There are many types of particulate matter in synovial fluid, and specific identification of these particles are challenging. We assessed synovial fluid samples from…
Abstract Number: 2270 • 2016 ACR/ARHP Annual Meeting
Inflammasome/IL-1β Activation Induced By Calcium Pyrophosphate Dihydrate Crystals Is Mainly Driven By a P2X7 Receptor-Independent Potassium Efflux
Laure Campillo-Gimenez¹, Félix Renaudin², Pierre Bobé³, Marjolaine Gosset⁴, Christèle Combes⁵, Martine Cohen-Solal^2,6, Frederic Lioté^2,6 and Hang-Korng Ea^2,6, ¹Hôpital Lariboisière, Centre Viggo Petersen, INSERM UMR1132, Paris Diderot University, Paris, France, ²INSERM UMR1132, Paris Diderot University, Paris, France, ³INSERM UMRS757, Paris Sud University, Orsay, France, ⁴EA2496, Paris Descartes University, Montrouge, France, ⁵ENSIACET, CIRIMAT, INPT-UPS-CNRS, Toulouse, France, ⁶AP-HP, Lariboisière Hospital, Rheumatology Department, Paris, France
Background/Purpose: Calcium pyrophosphate crystals including monoclinic and triclinic dihydrate phases (m- and t-CPPD) are found in 40% of end-stage osteoarthritis (OA) patients. Frequently asymptomatic, it…
Abstract Number: 2271 • 2016 ACR/ARHP Annual Meeting
Mutation in Osteoprotegerin Gene: Early-Onset Osteoarthritis and Chondrocalcinosis in a US Family of Italian/German Ancestry
Urooj Qazi¹, Charlene J. Williams², Mark L. Bernstein³, Aaron Charniak⁴, Amaryllis Ortiz², Ann K. Rosenthal⁵, Lucien Cardinal¹ and Alan T. Kaell¹, ¹Internal Medicine, SUNY Stony Brook Medicine-John T Mather Memorial Hospital, Port Jefferson, NY, ²Department of Biomedical Sciences, Cooper Medical School of Rowan University, Camden, NJ, ³Rheumatology, SUNY Stony Brook Medicine-John T Mather Memorial Hospital, Stony Brook, NY, ⁴SUNY Stony Brook Medicine-John T Mather Memorial Hospital, Port Jefferson, NY, ⁵Division of Rheumatology, Medical College of WI, Milwaukee, WI
Background/Purpose: Chondrocalcinosis is characterized by calcium pyrophosphate dihydrate (CPPD) deposition in articular cartilage. It can occur as a rare autosomal dominant disorder with florid early-onset…
Abstract Number: 2272 • 2016 ACR/ARHP Annual Meeting
The Influence of Genetic Variants on Renal Uric Acid Excretion in Response to Frusemide
Nicola Dalbeth¹, Jordyn de Kwant¹, Gregory Gamble², Amanda Phipps-Green³, Anne Horne², Robert Doughty¹, Lisa K. Stamp⁴ and Tony R. Merriman⁵, ¹University of Auckland, Auckland, New Zealand, ²Department of Medicine, University of Auckland, Auckland, New Zealand, ³University of Otago, Dunedin, New Zealand, ⁴University of Otago, Christchurch, New Zealand, ⁵Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: Diuretic use is strongly associated with development of hyperuricaemia and gout. Genetic variation in the renal uric acid transporters SLC2A9 (encoding GLUT9) and SLC22A11…
Abstract Number: 2273 • 2016 ACR/ARHP Annual Meeting
Trans-Ancestral Meta-Analysis Identifies Nine New Loci Associated with Serum Uric Acid Concentrations
James Boocock¹, Eli A. Stahl², David B. Mount³, Tony R. Merriman⁴, Hyon K. Choi⁵, Yukinori Okada⁶, Murray Cadzow¹ and Ruth Topless¹, ¹University of Otago, Dunedin, New Zealand, ²Divisions of Rheumatology and Genetics, Brigham and Women's Hospital, Boston, MA, ³Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁴Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ⁵Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, ⁶Osaka University, Osaka, Japan
Background/Purpose: Serum uric acid is an important biomarker for gout disease and kidney function. Genome-wide association study (GWAS) meta-analyses have identified 28 loci in…
Abstract Number: 2274 • 2016 ACR/ARHP Annual Meeting
Evidence of Phospho-Degron Regulating Expression of Urate Secretory Transporter ABCG2
Alexis Hofherr¹, Meng Li², Michael Kottgen¹ and Owen M. Woodward², ¹Nephrology, University of Freiburg Medical Center, Freiburg, Germany, ²Physiology, University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: ABCG2 is a high capacity urate secretory transporter of the renal proximal tubule. The common Q141K ABCG2 mutation causes gout in humans through an…
Abstract Number: 2275 • 2016 ACR/ARHP Annual Meeting
Genome-Wide Association Study of Gout in New Zealand Polynesian People
Tanya Flynn¹, Ruth Topless¹, Murray Cadzow¹, Amanda Phipps-Green¹, Nick Burns¹, Nicola Dalbeth², Lisa K. Stamp³, Jennie Harre Hindmarsh⁴ and Tony R. Merriman⁵, ¹University of Otago, Dunedin, New Zealand, ²University of Auckland, Auckland, New Zealand, ³University of Otago, Christchurch, New Zealand, ⁴Ngati Porou Hauora Charitable Trust, Te Puia Springs, New Zealand, ⁵Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand
Background/Purpose: The prevalence of gout in New Zealand Polynesian (Māori and Pacific) populations is approximately twice that of the New Zealand European population, with a…
Abstract Number: 2276 • 2016 ACR/ARHP Annual Meeting
Pleiotropic Effect of ABCG2 in Gout
Tony R. Merriman¹, Amanda Phipps-Green², James Boocock², Philip Riches³, Anne-Kathrin Tausche⁴, Timothy Radstake⁵, Matthijs Janssen⁶, Leo .A.B. Joosten⁷, Tim L Jansen⁸, Alexander So⁹, Jennie Harre Hindmarsh¹⁰, Lisa K. Stamp¹¹, Nicola Dalbeth¹² and Rebekah Wrigley², ¹Biochemistry Dept, PO Box 56, University of Otago, Dunedin, New Zealand, ²University of Otago, Dunedin, New Zealand, ³University of Edinburgh, Edinburgh, United Kingdom, ⁴Medizinische Klinik und Poliklinik III, Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden, Dresden, Germany, ⁵Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, ⁶Department of Rheumatology, Rijnstate Hospital Arnhem, Arnhem, Netherlands, ⁷Internal Medicine, Radboud University Medical Center, Nijmegen, Netherlands, ⁸Rheumatology, Radboud University Medical Center, Nijmegen, Netherlands, ⁹Rheumatology Department, Lausanne University Hospital, Switzerland, Lausanne, Switzerland, ¹⁰Ngati Porou Hauora Charitable Trust, Te Puia Springs, New Zealand, ¹¹University of Otago, Christchurch, New Zealand, ¹²University of Auckland, Auckland, New Zealand
Background/Purpose: The ABCG2 Q141K (rs2231142) variant is an established cause of hyperuricaemia in Europeans. Although the effect size of ABCG2 rs2231142 on serum urate levels…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].